← Eichor
Study identifier: NCT05732779 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients

Condition: Heart Transplant Rejection · Immune Suppression · Pediatric Heart Transplant  ·  Sponsor: University of Florida

PhaseNA
Planned participants100
Who can joinAll sexes, 10 Years to 21 Years
Healthy volunteersNo

About this study

We will conduct a two-group randomized controlled trial to examine the eMocha DOT intervention with pediatric HT recipients.In this population, medication nonadherence remains a primary cause of late acute rejection (LAR) episodes, increased number of hospitalizations, graft failure, and patient mortality. Herein, we propose an innovative approach to promote medication adherence and improve patient and graft outcomes.

This description comes directly from the study's public registry record.

Talk to the study team

Dipankar Gupta, MD  ·  352-273-5422  ·  dgupta@ufl.edu

Dalia Lopez-Colon, PhD  ·  352-281-6723  ·  dalylc@ufl.edu

Always discuss trial participation with your own doctor first.

Locations (4)

University of Miami, Miller School of MedicineCoral Gables, Florida, United StatesRecruiting
University of FloridaGainesville, Florida, United StatesRecruiting
Joe DiMaggio Children's HospitalHollywood, Florida, United StatesRecruiting
FSU College of MedicineTallahassee, Florida, United StatesNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05732779